Avalo CMO exercises options and sells 4,654 shares
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On June 30, 2026, Doyle sold 4,654 shares in an open-market sale at $20.00 per share, while also exercising options to acquire a total of 4,654 shares of common stock at strike prices of $8.04 and $12.65 per share. The options exercised relate to grants that vest over four years, and all transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the trades were pre‑scheduled rather than discretionary market timing.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,654 shares ($42K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
4,654 shs ($93K)
Approx. gross sale proceeds
$93K
Approx. exercise cost
$51K
Approx. pre-tax spread
$42K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,875 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 1,779 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,875 | $12.65 | $36K |
| Exercise | Common Stock | 1,779 | $8.04 | $14K |
| Sale | Common Stock | 4,654 | $20.00 | $93K |
Holdings After Transaction:
Stock Option (Right to Buy) — 240,842 contracts (Direct);
Common Stock — 51,776 shares (Direct)
Footnotes (3)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
- F3. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 4,654 shares
Sale price: $20.00/share
Options exercised (8.04): 1,779 shares at $8.04
+4 more
7 metrics
Shares sold
4,654 shares
Open-market sale of common stock at $20.00 per share on June 30, 2026
Sale price
$20.00/share
Price for 4,654 common shares sold in open-market transaction
Options exercised (8.04)
1,779 shares at $8.04
Common stock acquired via option exercise on June 30, 2026
Options exercised (12.65)
2,875 shares at $12.65
Common stock acquired via option exercise on June 30, 2026
Rule 10b5-1 plan adoption
November 13, 2025
Date the trading plan governing these transactions was adopted
Option expiration (8.04 strike)
January 28, 2035
Expiration date for stock option with $8.04 exercise price
Option expiration (12.65 strike)
July 15, 2034
Expiration date for stock option with $12.65 exercise price
Key Terms
Rule 10b5-1 trading plan, stock option, Exercise or conversion of derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option financial
"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"the remainder will vest in equal monthly installments over the following three (3) years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Avalo Therapeutics (AVTX) insider Mittie Doyle report in this Form 4?
Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, reported an exercise-and-sell transaction. She exercised stock options for 4,654 common shares and sold 4,654 shares in an open-market trade, aligning the sale size with the options exercised on the same date.
What stock options did Mittie Doyle exercise in Avalo Therapeutics (AVTX)?
She exercised options covering 1,779 shares at an $8.04 strike price and 2,875 shares at a $12.65 strike price. These options convert into common stock and are tied to multi-year vesting schedules described in the accompanying footnotes.
Were Mittie Doyle’s Avalo Therapeutics (AVTX) trades pre-planned under Rule 10b5-1?
Yes. The Form 4 states that all reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing considerations for these sales.
What are the expiration dates of the Avalo Therapeutics (AVTX) options exercised by Mittie Doyle?
The options exercised include grants expiring on July 15, 2034 and January 28, 2035. Each option grant vests 25% on its initial vesting date, with the remaining portion vesting in equal monthly installments over the following three years, contingent on continued service.
How do the vesting terms affect Mittie Doyle’s Avalo Therapeutics (AVTX) option grants?
Each option grant vests 25% on a specified initial date, then vests monthly over three years. Continued service with Avalo Therapeutics is required for each vesting installment, meaning future option availability depends on ongoing employment at those vesting dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
